Biopharmadive iconBiopharmadiveSep 2, 2026

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Share this story

Send the public story page.

Useful takeaways from this story.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Building the complete brief

The page is ready to read now. The fuller skim-friendly version will appear here automatically.

The useful part

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app